Company intelligence / Profile preview

Cellmedix Holdings

Fort Myers, Florida, United States

Ownership: Private
Development stage: Other

Overview

Cellmedix Holdings developed and commercialized the Centrepid Platelet Concentrator, a platelet-rich plasma (PRP) preparation system used for autologous regenerative biologic procedures; all assets, including the 510(k)-cleared device and associated patents, were acquired by EmCyte Corporation in 2020, after which the technology continued commercially under EmCyte.[2][4][5][7]

Therapeutic areas: NeurologyOther
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

EmCyte (acquisition and integration of Centrepid Platelet Concentrator system)[2][4][5]

Beyond the preview

Go deeper on Cellmedix Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellmedix Holdings.

Explore the full profile